Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

osts related to the Phase 3 clinical program for lorcaserin hydrochloride, Arena's drug candidate for the treatment of obesity. Research and development expenses included $1.0 million in non-cash, share-based compensation expense in each of the quarters ended March 31, 2008 and 2007. General and administrative expenses totaled $8.9 million in the first quarter of 2008, compared to $4.9 million in the first quarter of 2007. This increase in general and administrative expenses is primarily attributable to increases in patent costs and personnel-related expenses. Total patent costs, including patent costs related to partnered programs, increased by $1.7 million in the first quarter of 2008 compared to the first quarter of 2007. General and administrative expenses in the first quarter of 2008 included $1.4 million in non-cash, share-based compensation expense, compared to $0.9 million in the first quarter of 2007.

Cash, cash equivalents and short-term investments totaled $333.6 million at March 31, 2008. Approximately 73.8 million shares of common stock were outstanding at March 31, 2008.

Arena's First Quarter Highlights

o Initiated a Phase 2b clinical trial of APD125, an oral drug candidate

intended to reduce insomnia symptoms and improve sleep maintenance and

quality. This Phase 2b trial is a double-blind, randomized,

placebo-controlled subjective study that is expected to enroll

approximately 675 patients in about 70 clinical sites in the United

States.

o Reported that, following a planned review by an independent

Echocardiographic Safety Monitoring Board, or ESMB, Arena is continuing

BLOOM, a pivotal clinical trial evaluating the efficacy and safety of

lorcaserin for the treatment of obesity. The ESMB's review of unblinded

echocardiographic data performed after all patients had the opportunity

to complete 12 months of dosing in the trial confirmed that d
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Decision Resources Group finds that the ... Russia , India and ... in 2013, roughly equal to the size of the ... BRIC market will experience much faster growth as a result of ... Other key findings from Decision Resources Group,s coverage of ...
(Date:8/20/2014)... nerves in your ear could improve the health of ... the University of Leeds used a standard TENS machine ... electrical pulses to the tragus, the small raised flap ... of the ear canal. , The stimulation changed the ... reducing the nervous signals that can drive failing hearts ...
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets  has announced ... Global Strategic Business Report" report to their offering. ... Culture Supplies in US$ Thousands by the following Product Segments: Media, ... for the US, Canada , Japan ... , and Latin America . Annual estimates and ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... Wis. Berbee Information Networks Corporation , a ... & Solutions LLC for an undisclosed sum. , ,Berbee said ... firm, bringing it to about 630 employees in all. Strategies ... IBM's iSeries line of business servers. , ,Berbee has ...
... new version of its Mediasite presentation recorder for the Japanese ... date and hopes to create a bigger market. , ,Mediasite ... as a PowerPoint deck with a video of the speaker ... , ,According to company statements the Japanese market is attractive ...
... Manufacturing Company in Racine is providing heat-transfer components ... , the company said on Wednesday. , ,The parts ... company's new hybrid vehicle. Modine's mass heat transfer ... which is the car's main energy source. , ,The ...
Cached Biology Technology:Modine explores making components for fuel cell vehicles 2Modine explores making components for fuel cell vehicles 3
(Date:8/19/2014)... increasing caesarean section rate, suggests a new commentary published ... of Obstetrics and Gynaecology (BJOG) . , China has ... world. Of 16 million babies born in 2010, approximately ... not known, the current Chinese language literature on caesarean ... 36% to 58%. However, before the 1980s, the caesarean ...
(Date:8/19/2014)... Can nutrition rating systems be used in supermarkets to ... University researchers sought to answer that very question by ... uses the Guiding Stars System to rate the nutritional ... Cornell Food and Brand Lab,s David Just, PhD, and ... studied the sales records of over 150 Hannaford Supermarkets ...
(Date:8/19/2014)... Long-Term Ecological Research and Network-Level Science, , Imagine if ... range of ecosystems was responding to global changes in ... if it coupled multiple decades of information about ecological ... models from dozens of different ecosystem types. , ... Ecological Research (LTER) Network, which will soon celebrate its ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3This week from AGU: Long-term ecological research, predicting cholera outbreaks 2
... and frogs are about to take up residence in the ... and scientists want to learn more about the water-running lizard,s ... that means how it increases its locomotion efficiency by producing ... its recovery stroke. And these engineers are surprised at ...
... suggests, you can,t digest resistant starch so it ends up ... entered your mouth. As unlovely as that seems, once in ... decreasing bowel pH and transit time, and increasing the production ... good bugs while keeping bad bugs at bay. A University ...
... believe that findings from fieldwork along the North Yorkshire ... of 180 million years ago and current climate predictions ... they,ve shown how higher temperatures and lower oxygen levels ... the Jurassic seas eventually recovered from the effects of ...
Cached Biology News:Nature's phenomena might teach Virginia Tech engineers new tricks 2Nature's phenomena might teach Virginia Tech engineers new tricks 3Study shows that diet of resistant starch helps the body resist colorectal cancer 2Jurassic records warn of risk to marine life from global warming 2